Otsuka Pharmaceutical and ShapeTX have announced a significant collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for the treatment of ocular diseases, with the option to expand the scope of their work to include additional targets and tissue types.
This collaboration brings together ShapeTX's AAVidTM capsid discovery platform and transgene engineering technology with Otsuka's expertise in genetic payload design and ophthalmology to create innovative therapies for individuals affected by serious eye conditions.
According to the terms of the agreement, ShapeTX will receive an initial payment from Otsuka and stands to receive further payments tied to development, regulatory milestones, and sales achievements, with the total potential value of these payments exceeding $1.5 billion. Additionally, ShapeTX will be entitled to receive tiered royalties on the sales of any products resulting from this collaborative effort.
The primary objective of this collaboration with ShapeTX is to enable the delivery of vectorised antibody drugs alongside AAV technology. This approach is designed to specifically target disease-related cell types within the eye and offer a one-time, curative treatment with sustained lifetime expression.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!